Exposure to Oral S-ketamine Is Unaffected by Itraconazole but Greatly Increased by Ticlopidine
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at intervals of 4 weeks. Ticlopidine treatment increased the mean area under the plasma concentration-time curve extrapolated to infinity (AUC(0-∞)) of oral ketamine by 2.4-fold (P < 0.001), whereas itraconazole treatment did not increase the exposure to S-ketamine. The ratio of norketamine AUC(0-∞) to ketamine AUC(0-∞) was significantly decreased in the ticlopidine (P < 0.001) and itraconazole phases (P = 0.006) as compared to placebo. In the ticlopidine and itraconazole phases, the areas under the effect-time curves (self-reported drowsiness and performance) were significantly higher than those in the placebo phase (P < 0.05). The findings suggest that the dosage of S-ketamine should be reduced in patients receiving ticlopidine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The use of analogue scales in rating subjective feelings
BOND, A., & LADER, M. (1974) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1974.tb02285.x · Cited by 1,972
Effects of the Antifungal Agents on Oxidative Drug Metabolism: Clinical Relevance
Venkatakrishnan, K., von Moltke, L. L., & Greenblatt, D. J. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038020-00002 · Cited by 508
Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans
Clements, J. A., Nimmo, W. S., & Grant, I. S. (1982) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600710516 · Cited by 420
Itraconazole drastically increases plasma concentrations of lovastatin and lovastatin acid
Neuvonen, P. J., & Jalava, K.-M. (1996) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(96)90167-8 · Cited by 238
Self-citationUse of oral ketamine in chronic pain management: A review
Blonk, M. I., Koder, B. G., van den Bemt, P. M. L. A., & Huygen, F. J. P. M. (2010) · European Journal of Pain · doi:10.1016/j.ejpain.2009.09.005 · Cited by 168
Cited by
Ketamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy
Peltoniemi, M. A., Hagelberg, N. M., Olkkola, K. T., & Saari, T. I. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0383-6 · Cited by 672
Self-citationZanger, U. M., & Klein, K. (2013) · Frontiers in Genetics · doi:10.3389/fgene.2013.00024 · Cited by 345
Metabolism and metabolomics of ketamine: a toxicological approach
Dinis-Oliveira, R. J. (2017) · Forensic Sciences Research · doi:10.1080/20961790.2017.1285219 · Cited by 178
“cantly reduces the plasma concentrations of ketamine and norketamine after oral administration of S-ketamine; this effect was only moderately registered after its intravenous administration [73,74].”
Background(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice
Yamaguchi, J.-I., Toki, H., Qu, Y., Yang, C., Koike, H., Hashimoto, K., Mizuno-Yasuhira, A., & Chaki, S. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0084-y · Cited by 105
Role of Cytochrome P4502B6 Polymorphisms in Ketamine Metabolism and Clearance
Rao, L. K., Flaker, A. M., Friedel, C. C., & Kharasch, E. D. (2016) · Anesthesiology · doi:10.1097/aln.0000000000001392 · Cited by 67
Metadata
- Authors
- Peltoniemi, M. A., Saari, T. I., Hagelberg, N. M., Reponen, P., Turpeinen, M., Laine, K., Neuvonen, P. J., & Olkkola, K. T.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2011-06-29
- Volume
- 90
- Issue
- 2
- Pages
- 296-302
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2074581066
- Cited by
- 54
- References
- 5
- FWCI
- 3.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.